Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

ITP following treatment of multiple sclerosis patients with alemtuzumab in CAMMS223: Case reports and risk management plan implementation

ITP following treatment of multiple sclerosis patients with alemtuzumab in CAMMS223: Case reports and risk management plan implementation. Multiple Sclerosis. 2006; 12(Supplement 1 (Late Breaking)):P800.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.